| abstract |
N-acylamino aryl derivatives of the general formula (1) wherein: R1 is halogen, halogen-C1-6 alkyl, cyano, C1-6 alkoxy or halogen-C1-6 alkoxy; R21, R22, R23 and R24 independently from each other are selected from the group consisting of hydrogen, C1-6 alkyl, halogen, halogen (C1-6) alkyl, hydroxyl, C1-6 alkoxy or -CHO; R3 is hydrogen or C1-3 alkyl; R4 and R5 independently of each other, are selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 alkoxy or -COO (C1-6 alkyl); or R4 and R5 together with the C atom to which a C3-7 cycloalkyl ring is attached; R6 is -CO-NR7R8; -COO (C1-6 alkyl), -CN, -NR2 or -NHC (O) R; R7 and R8 independently of each other, are selected from the group consisting of hydrogen, C1-6 alkyl, NH2 or hydroxyl; R is hydrogen or C1-6 alkyl; n is 0, 1, 2 or 3, X is -CHRO, -OCHR-, -CH2S-, -SCH2-, -CH2CH2-, -CH = CH- or -C? C-; and pharmaceutically active acid addition salts thereof, procedures, medications and use. It has been found that the compounds of the general formula (1) are selective inhibitors of monoamine oxidase, and are therefore useful in the treatment of diseases mediated by monoamine oxidase B inhibitors, for example, for the treatment of Alzheimer's disease or senile dementia. |